Drug Trial Radar · NCT05035641
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
Last checked: Nov 19, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Oct 18, 2021
Primary completion
Jul 5, 2023
Study completion Jul 24, 2023
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients
Conditions
- Renal Anemia
Interventions
AND017Drug
Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
PlaceboDrug
Orally, 3 times per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationsTime frame: Up to 17 weeks
- Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosingTime frame: Up to 5 weeks after dosing
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Amicis Research Center
Northridge, California
Clinical Site Partners
Winter Park, Florida
Northwest Louisiana Nephrology
Shreveport, Louisiana
Elite Research Center
Flint, Michigan
Metrolina Nephrology Associates
Charlotte, North Carolina
Southeast Renal Research Institute
Chattanooga, Tennessee
Clinical Advancement Center, PLLC
San Antonio, Texas
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.